Treatment Options After Adalimumab and Methotrexate Failure

Introduction to Alternative Therapies

The American Gastroenterological Association recommends switching to a different TNF inhibitor, such as infliximab, or transitioning to an alternative mechanism biologic, like ustekinumab or vedolizumab, after adalimumab and methotrexate failure, with moderate certainty evidence 1
The European League Against Rheumatism suggests that patients with rheumatoid arthritis who have failed a first TNF inhibitor should receive another TNF inhibitor, abatacept, rituximab, or tocilizumab, based on strong recommendations and moderate-quality evidence 2

For patients with Crohn's disease, infliximab is the preferred next-line agent after adalimumab failure, supported by indirect evidence and strong recommendations 1
Ustekinumab represents a strong alternative for Crohn's disease, particularly in cases of secondary loss of response to adalimumab, with strong recommendation and moderate certainty evidence for induction of remission 1
The American College of Gastroenterology recommends that patients with Crohn's disease who previously responded to one TNF inhibitor can be switched to adalimumab, ustekinumab, or vedolizumab for induction of remission, based on high-quality evidence 1

Serious infections occurred at a rate of 2.03 per 100 patient-years in long-term studies of adalimumab, and these effects may persist, highlighting the need for careful monitoring 4
Autoimmune reactions, including lupus-like syndrome and vasculitis, have been documented with adalimumab, emphasizing the importance of surveillance 4
Methotrexate may be added to the new biologic agent if the previous side effects were primarily gastrointestinal intolerance, as combination therapy generally improves outcomes, according to the American College of Rheumatology 1, 6, 5

The American College of Gastroenterology recommends optimizing new biologic therapy by using infliximab at 5 mg/kg at weeks 0, 2, 6, then every 8 weeks, and considering combination with methotrexate to reduce antibody formation, based on high-quality evidence 1, 6
Delaying switching therapy while waiting for adalimumab side effects to fully resolve should be avoided, as ongoing disease activity causes irreversible damage, according to the European League Against Rheumatism 1, 2
Assuming all TNF inhibitors will cause the same side effects is incorrect, as infliximab has a different administration route and pharmacokinetic profile than adalimumab, highlighting the need for individualized treatment approaches 1